ArticleNeurology(R) neuroimmunology & neuroinflammation2020
Direct economic burden of patients with autoimmune encephalitis in western China.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions.Frontiers in neurology · 2025Pooled it
- Efficacy of immunotherapy and prognosis in anti-LGI1 encephalitis patients: A meta-analysis.Annals of clinical and translational neurology · 2023Pooled it
- Second-line immunotherapy and functional outcomes in autoimmune encephalitis: A systematic review and individual patient data meta-analysis.Epilepsia · 2022Pooled it
- Autoimmune Encephalitis in Acute Care-Pathology, Diagnosis, and Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Hospital resource use and costs in autoimmune encephalitis: a single-center retrospective cohort study.Neurological research and practice · 2026Article
- Predictors of return to work status among patients with autoimmune encephalitis at one year post-discharge: a prospective observational study.BMC neurology · 2025Observational
- A retrospective study of insurance coverage status and economic cost of rare diseases in Hainan Province.Scientific reports · 2025Article
- Treatment and prognosis of failure of first-line immunotherapy or recurrent autoimmune encephalitis patients with ofatumumab-a fully human anti-CD20 mAb.Frontiers in neurology · 2025Review
- Article
- Differentiation between viral and autoimmune limbic encephalitis: a prospective cohort study with development and validation of a diagnostic model.Journal of neurology · 2024Observational
- Phenotyping the late- and younger-onset neuronal surface antibody-mediated autoimmune encephalitis: a multicenter study.Clinical and experimental immunology · 2023Article
- Limitations on knowledge of autoimmune encephalitis and barriers to its treatment among neurologists: a survey from western China.BMC neurology · 2023Article
- Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.Journal of neurology · 2022Observational
- Elevated ApoB/ApoA-I ratio is associated with acute anti-N-Methyl-D-aspartate receptor encephalitis, but not disease outcomes.Frontiers in neurology · 2022Article
- Elevated plasma D-dimer levels in patients with anti-N-methyl-D-aspartate receptor encephalitis.Frontiers in neurology · 2022Article
- Risk Prediction Models for Early ICU Admission in Patients With Autoimmune Encephalitis: Integrating Scale-Based Assessments of the Disease Severity.Frontiers in immunology · 2022Article
- The Antibody Assay in Suspected Autoimmune Encephalitis From Positive Rate to Test Strategies.Frontiers in immunology · 2022Article
- Neuropsychological Sequelae, Quality of Life and Adaptive Behavior in Children and Adolescents with Anti-NMDAR Encephalitis: A Narrative Review.Brain sciences · 2021Review
- Disturbance of Gut Bacteria and Metabolites Are Associated with Disease Severity and Predict Outcome of NMDAR Encephalitis: A Prospective Case-Control Study.Frontiers in immunology · 2021Observational
- Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the cost of autoimmune encephalitis (AE) in China for the first time.
methodsPatients who were newly diagnosed with antibody-positive AE (anti-NMDA receptor [NMDAR], anti-γ aminobutyric acid type B receptor [GABA
resultsOf the 208 patients reviewed, the mean direct cost per patient was renminbi (RMB) 94,129 (United States dollars [USD] 14,219), with an average direct medical cost of RMB 88,373 (USD 13,349). The average inpatient cost per patients with AE was RMB 86,810 (USD 13,113). The direct nonmedical cost was much lower than the direct medical cost, averaging RMB 5,756 (USD 869). The direct cost of anti-LGI1/CASPR2 encephalitis was significantly lower than that of anti-NMDAR encephalitis and anti-GABA
conclusionsThe financial burden of AE is heavy for Chinese patients, and there are significant differences between different types of AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.